The Australia vaccines market was valued at $0.6 billion in 2023, and is projected to reach $1.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.
Report Code : A325353 | Pages : 90 | Category : Life Sciences
The UK vaccines market was valued at $1.4 billion in 2023, and is projected to reach $3.0 billion by 2033, growing at a CAGR of 7.7% from 2024 to 2033.
Report Code : A325352 | Pages : 150 | Category : Life Sciences
The U.S. vaccines market was valued at $16.4 billion in 2023, and is projected to reach $29.1 billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033.
Report Code : A325351 | Pages : 90 | Category : Life Sciences
The Asia-Pacific vaccines market was valued at $9.8 billion in 2023, and is projected to reach $19.9 billion by 2033, growing at a CAGR of 7.3% from 2024 to 2033.
Report Code : A325350 | Pages : 130 | Category : Life Sciences
The Europe vaccines market was valued at $12.1 billion in 2023, and is projected to reach $22.3 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.
Report Code : A325349 | Pages : 150 | Category : Life Sciences
The North America vaccines market was valued at $18.0 billion in 2023, and is projected to reach $32.1 billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033.
Report Code : A325348 | Pages : 110 | Category : Life Sciences
The global newcastle disease vaccine market was valued at $0.4 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 4.4% from 2024 to 2033.
Report Code : A324484 | Pages : 216 | Category : Life Sciences
The Asia-Pacific dengue virus diagnostic test market size was valued at $ 53.25 million in 2023 and is projected to reach $ 99.45 million by 2035, registering a CAGR of 5.3% from 2024 to 2035.According to the report published by the Allied Market Research, the
Report Code : A325386 | Pages : 300 | Category : Life Sciences
